BFM
IGMS

Boothbay Fund Management’s IGM Biosciences IGMS Stock Holding History

Boothbay Fund Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,139
Closed -$338K – 2016
2021
Q3 		$338K Buy
+5,139
New +$393K 0.01% 1266

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boothbay Fund Management's IGMS Position: Q4 2021 in Review

Boothbay Fund Management sold out of IGM Biosciences (IGMS) in Q4 2021, closing a stake of 5,139 shares — an estimated $338K sold.

Boothbay Fund Management first reported a position in IGMS in Q3 2021 and held it in 1 quarter. The position peaked at $338K in Q3 2021. 87 funds tracked by Wall St. Rank hold IGMS as of Q4 2021.

  • Boothbay Fund Management reported no remaining IGM Biosciences position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 5,139 IGM Biosciences shares in Q4 2021, an estimated $338K.
  • Boothbay Fund Management first reported a position in IGM Biosciences in Q3 2021 and held it in 1 quarter.
  • Boothbay Fund Management's IGM Biosciences position peaked at $338K in Q3 2021.
  • 87 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.